Padmanee Sharma, M.D., Ph.D.
The future of immunotherapy and clinical trials
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment InformationDepartment of Genitourinary Medical Oncology, Division of Cancer Medicine
2003 | Board Certified Medical Oncology |
2000 | Board Certified Internal Medicine |
Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2014
Associate Professor, Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2014
Assistant Professor, Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2010
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2010
Fellow, Memorial Sloan-Kettering Cancer Center, New York, NY, 2000 - 2004
Resident, New York Hospital, Cornell Medical Center, New York, NY, 1998 - 2000
Member, Promotion & Tenure Committee, 2015 - 2016
Member, Organizing Committee for the 2013 Symposia on Cancer Research: Genomic Medicine, 2012 - 2013
Member, Technology Review Committee, 2012 - 2014
Member, Multidisciplinary Research Advisory Committee, 2009 - 2012
T.C. and Jeanette Hsu Endowed Chair in Cell Biology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Hummingbird Bioscience, San Francisco, CA, 2019 - Present
Optera Therapeutics, Emeryville, CA, 2019 - Present
Dragonfly Therapeutics, Waltham, MA, 2019 - Present
BioMx, Israel, 2018 - Present
Forty Seven, Inc, Menlo Park, CA, 2018 - Present
Polaris Pharmaceuticals, San Diego, CA, 2018 - Present
Apricity Therapeutics, Inc, San Francisco, CA, 2018 - Present
Marker Therapeutics, Houston, TX, 2018 - Present
Codiak Biosciences, Cambridge, MA, 2018 - Present
ImaginAB, Inglewood, CA, 2018 - Present
Merck Sharp & Dohme Corp, Washington, DC, 2017 - Present
Pieris Pharmaceuticals, Inc, Boston, MA, 2017 - 2018
Oncolytics Biotech Advisory Board, Barbados, 2017 - Present
Constellation Advisory Board, Boston, MA, 2017 - Present
BioAtla LLC, San Diego, CA, 2017 - Present
GSK Biomarkers Advisory Board, Philadelphia, PA, 2015 - Present
Kite Pharma Inc Advisory Board, Santa Monica, CA, 2015 - 2018
Neon Advisory Board Therapeutics, Boston, MA, 2015 - Present
BMS Immuno-Oncology Network, The Woodlands, TX, 2014 - 2015
Jounce Therapeutics Advisory Board, Cambridge, MA, 2012 - Present
PROVENGE® (sipuleucel-T) Mechanism of Action Clinical Advisory Board, Washington, DC, 2011 - Present
Avastin Renal Cell Carcinoma Regional Advisory Board, San Francisco, CA, 2010 - Present
Dendreon Advisory Board, Seattle, WA, 2009 - Present
Ipilimumab Prostate Advisory Board, New York, NY, 2009 - Present
Bristol-Myers Squibb Immunology Biomarker Advisory Board, Miami, FL, 2008 - Present
2009 | MD Anderson Cancer Center Prostate Cancer SPORE Development Award |
2007 | The Gillson Longenbaugh Foundation, Award Recipient |
2005 | National Institute of Health Renewal Clinical Loan Repayment Program Award |
2003 | GSK National Medical Oncology Fellows Forum, Award Recipient |
2002 | Doris Duke, Symposium Award for Abstract Presentation |
Title: | Determining Regulatory T-Cell Influences on Effector T-Cell Function in Prostate Cancer Patients |
Funding Source: | The University of Texas MD Anderson Cancer Center Institutional Research Grant |
Role: | Principal Investigator |
Title: | Effector and Regulatory T cell Responses in Prostate Cancer Patients |
Funding Source: | Cancer Research Institute Clinical Investigator Grant |
Role: | Principal Investigator |
Title: | Identification and Correlation of Immune Responses and Tumor Responses in Transitional Cell Carcinoma Patients Treated with Immunotherapy Agents |
Funding Source: | American Society of Clinical Oncology (ASCO) |
Role: | Principal Investigator |
Title: | Characterizing Immunological Responses for Correlation with Clinical Outcome in Prostate Cancer Patients Treated with Anti-CTLA-4 Therapy in the Neoadjuvant Setting |
Funding Source: | Prostate Cancer Foundation Young Investigator Award |
Role: | Principal Investigator |
Title: | Defining the Role of ICOS-expressing T Cells Against Melanoma |
Funding Source: | Melanoma Research Alliance Young Investigators Award |
Role: | Principal Investigator |
Title: | Identification and Correlation of Immune Responses and Tumor Responses in Transitional Cell Carcinoma Patients Treated with NY-ESO-1 Vaccine |
Funding Source: | The University of Texas MD Anderson Cancer Center Physician Scientist Training Program Award |
Role: | Principal Investigator |
Title: | Enhancing Immune Responses Against Bladder Cancer |
Funding Source: | The Gillson Longenbaugh Foundation |
Role: | Principal Investigator |
Title: | CTLA-4 Blockade in Therapy of Prostate Cancer |
Funding Source: | American Cancer Society (ACS) |
Role: | Principal Investigator |
Title: | Blockade of CTLA-4 to Induce Effective Anti-tumor Immune Responses in Cancer Patients |
Funding Source: | Doris Duke Charitable Foundation |
Role: | Principal Investigator |
Title: | Enhancing Immune Responses Against Bladder Cancer |
Funding Source: | Carl C. Anderson Sr. & Marie Jo Anderson Charitable Foundation |
Role: | Principal Investigator |
Title: | Enhancing Immune Responses Against Bladder Cancer |
Funding Source: | The Gillson Longenbaugh Foundation |
Role: | Principal Investigator |
Title: | Targeting NY-ESO-1 and Other Novel Tumor Antigens for Cancer Immunity |
Funding Source: | The University of Texas MD Anderson Cancer Center Shooting Down Cancer Institutional Research Grant |
Role: | Principal Investigator |
Title: | Studying Immune Responses to the NY-ESO-1 Antigen in Transitional Cell Carcinoma |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | CTLA-4 Blockade in Therapy of Prostate Cancer: Therapeutic Mechanisms and New Directions |
Funding Source: | Prostate Cancer Foundation Challenge Award |
Role: | Co-Investigator |
Title: | ICOS-expressing T Cells as Mediators of Antitumor Immune Responses |
Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
Role: | Principal Investigator |
Title: | Immunologic Effect of Anti-CTLA-4 Therapy on Prostate Cancer (CL 30924) |
Funding Source: | MD Anderson Cancer Center Prostate SPORE Development Research Project |
Role: | Project Leader |
Title: | Combining Local Ablation Plus Systemic Immunotherapy to Improve Anti-Tumor Responses in Renal Cell Carcinoma |
Funding Source: | MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program |
Role: | Co-Investigator |
Title: | Immunogenomics Investigations on a Presurgical trial to Evaluate Biomarkers of Immune Checkpoint Blockade |
Funding Source: | NIH-Bladder SPORE DRP Pilot Project |
Role: | Project Leader |
Title: | Combination Immunotherapy with Trastuzumab and a HER2-derived Peptide Vaccine In Breast Cancer |
Funding Source: | R. Lee Clark Fellows Award |
Role: | Mentor |
Title: | Reversing Vaccination Induced Impairment of Anti-CTLA-4 Based Cancer Therapy |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | |
Funding Source: | AACR SU2C-Phillip A. Sharp Award |
Role: | Co-Program Leader |
Title: | Identification and Analysis of Prostate Reactive TCRs for T cell Mediated Adoptive Cellular Immunotherapy of Metastatic Prostate Cancer |
Funding Source: | AACR SU2C-Phillip A. Sharp |
Role: | Co-Program Leader |
Title: | Collaboration Agreement |
Funding Source: | MD Anderson-GlaxoSmithKline LLC |
Role: | Co-Program Leader |
Title: | |
Funding Source: | MD Anderson-Janssen Biotech, Inc |
Role: | Co-Program Leader |
Title: | MDACC Sub-Award of the SU2C-Google(x) Immuno-Oncology Discovery Initiative |
Funding Source: | SU2C-Google(x) Immuno-Oncology |
Role: | Principal Investigator |
Title: | |
Funding Source: | MD Anderson-Bristol Myers Squibb |
Role: | Co-Program Leader |
Title: | |
Funding Source: | MD Anderson-Medimmune |
Role: | Co-Program Leader |
Title: | |
Funding Source: | MD Anderson-Pfizer |
Role: | Co-Program Leader |
Title: | |
Funding Source: | MD Anderson-Abbvie |
Role: | Co-Program Leader |
Title: | MD Anderson Cancer Center Prostate Cancer SPORE |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | A Feasibility Study to Determine T-Cell Responses to Neoantigens Following Treatment with Ipilimumab in Men with Metastatic Castration-Resistant Prostate Carcinoma |
Funding Source: | MD Anderson High Impact Clinical Research Support Program (HI-CRSP) |
Role: | Principal Investigator |
Title: | Exploring molecular & immune mechanisms of response & resistance to combined BRAF/MEK inhibition in patients with high-risk resectable metastatic melanoma |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-Investigator |
Title: | |
Funding Source: | NIH/NCI - Southwest Early Clinical Trials Consortium |
Role: | Co-Investigator |
Title: | Center Core Grants |
Funding Source: | CCSG |
Role: | Collaborator |